Evidence map›Paper›PMID 23346377›Full record

ArticleActa naturae2012

Recombinant influenza vaccines.

E S Sedova, D N Shcherbinin, A I Migunov, Iu A Smirnov, D Iu Logunov, M M Shmarov, L M Tsybalova, B S Naroditskiĭ, O I Kiselev, A L Gintsburg

Open access · bronzeAbstract read
PubMed Full text at PMC
In one paragraph

Article in Acta naturae, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 47 citations in OpenAlex.

  1. Review
  2. Message in a bottle: mRNA vaccination for influenza.The Journal of general virology · 2022
    Article
  3. Article
  4. Review
  5. Review
  6. Infection prevention in sarcoidosis: proposal for vaccination and prophylactic therapy.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2020
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

E S SedovaGamaleya Research Institute of Epidemiology and Microbiology, Gamaleya Str., 18, Moscow, Russia, 123098.
D N Shcherbinin
A I Migunov
Iu A Smirnov
D Iu Logunov
M M Shmarov
L M Tsybalova
B S Naroditskiĭ
O I Kiselev
A L Gintsburg
Gamalei Institute of Epidemiology and Microbiology · RUResearch Institute of Influenza · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This review covers the problems encountered in the construction and production of new recombinant influenza vaccines. New approaches to the development of influenza vaccines are investigated; they include reverse genetics methods, production of virus-like particles, and DNA- and viral vector-based vaccines. Such approaches as the delivery of foreign genes by DNA- and viral vector-based vaccines can preserve the native structure of antigens. Adenoviral vectors are a promising gene-delivery platform for a variety of genetic vaccines. Adenoviruses can efficiently penetrate the human organism through mucosal epithelium, thus providing long-term antigen persistence and induction of the innate immune response. This review provides an overview of the practicability of the production of new recombinant influenza cross-protective vaccines on the basis of adenoviral vectors expressing hemagglutinin genes of different influenza strains.

Indexed as

immunizationinfluenzaRecombinant vaccine

Identifiers

PMID23346377
PMCPMC3548171
OpenAlexW2164013942

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.